跳到正文
原文
STAT 主站· Vishal Khetpal·· 20 小时前AI 评分40

STREAM 试验:停用他汀类药物的老年患者预后不如继续用药者

Opinion: STAT+: I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins

AI 导读

在美国心脏协会年会上公布的 STREAM 试验结果显示,没有心肌梗死或中风史的老年患者停用他汀类药物后,预后不如继续用药者。尽管试验设计为非劣效性研究,但停药组患者健康状况较差,数据安全监测委员会建议停药患者应咨询医生恢复用药。

正文

At the American Heart Association’s recent annual meeting, the overarching theme coming from the center stage, bathed in Pantone red, was one of high-profile neutral findings.

As I listened to the results of the STREAM trial — which found that older adults without a history of heart attacks or strokes who stopped taking statins didn’t have significantly different outcomes from those who continued taking them — I jotted down that the study continued the theme.

But as the Kaplan-Meier curves were cast onto the screen, something felt off: The curves diverged, rather than stayed together. Theoretically, this scenario can happen in noninferiority studies, where researchers are testing whether an intervention offers similar outcomes compared with a standard. De-prescribing statins in this group, by the expectations set by researchers at the beginning of STREAM, was technically noninferior, but nevertheless, still inferior. The patients randomized to stop taking their statin did worse compared with those who continued. Even the trial’s data safety monitoring board suggested that patients who have stopped their statins should talk to their doctors about resuming their medications.

Continue to STAT+ to read the full story…

来源:STAT 主站 · statnews.com